fda statement bpc-157 panel backs compounded BPC-157, KPV peptides in win for RFK Jr BPC-157 – Mark Hyman, MD

Med Sci Monit Int Med J Exp Clin Res 25:666674 Zhou L et al (2023) N-homocysteinylation of -synuclein promotes its aggregation and neurotoxicity

When taken orally, peptides are notoriously unstable and difficult to deliver to the target location, meaning it would be very unlikely that it would reach the nucleus pulposus directly

The Regulatory Reality of 2026: What Actually Changed In late 2023, the FDA moved 19 peptides, including BPC-157, to what's known as "Category 2" status under its framework for bulk drug substances used in compounding, identifying them as substances that "may present significant safety risks." The concern, as stated in FDA guidance, centered on the limited large-scale human data and questions about immunogenicity

The initial research was almost entirely focused on gastroenterology

Your research deserves a reliable foundation